Condition: Coronary Disease · Coronary Artery Disease · Coronary Restenosis · Sponsor: Luzerner Kantonsspital
The purpose of the SIROOP Registry is to retrospectively and prospectively collect baseline, clinical and procedural characteristics of patients who have undergone PCI and are treated with either currently available sirolimus or paclitaxel coated DCBs (see Table 1), irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. Outcomes will be compared in different clinical subgroups. The impact of current DCBs in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.
This description comes directly from the study's public registry record.
Florim Cuculi, MD · +41412052134 · florim.cuculi@luks.ch
Matthias Bossard, MD · +41412051477 · matthias.bossard@luks.ch
Always discuss trial participation with your own doctor first.
| Luzerner Heart Centre | Lucerne, Canton of Lucerne, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04988685